Axsome Therapeutics, Inc.

AXSM Healthcare Biotechnology

Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024. In the quarter to June 2026, revenue grew 45.5%, EPS fell 2.06%, free cash flow fell 2.98% and total debt rose 4.66%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

157.14 4.65 −2.87%
Market cap
$8.5B
P/E
0.0×
Fwd P/E
−121×
Dividend yield
—
F-score
5/9
Altman Z
6.91
Beneish M
−2.53
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 5 5 5
ROE
(275.50%) (252.11%) (349.38%) (245.10%)
ROA
(37.30%) (29.11%) (28.74%) (27.35%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(111.61%) (86.93%) (109.12%) (97.28%)
Average Days of Receivables
127.79 128.32 129.39 130.41
Free Cash Flow per Share
(2.03) (1.89) (1.39) (1.39)
Free Cash Flow
(101.39) (93.88) (70.99) (71.96)
Capital Expenditures
(0.44) (0.48) (0.26) (0.70)
Other line items
Cash ROIC
(19.45%) (17.61%) (14.69%) (13.57%)
Accounts Receivable Turnover
3.50 3.48 3.43 3.26
Accounts Payable Turnover
0.77 0.69 0.55 0.62
Inventory Turnover
2.40 2.17 2.19 1.87
Average Days of Payables
433.46 503.83 743.05 548.71
Days of Inventory on Hand
190.03 214.78 219.46 263.23
Tax Rate
0.00 (0.01) 0.00 0.00
Research and Development Expense of Revenue
33.76% 28.70% 26.99% 24.19%
Selling, General and Administrative Expense of Revenue
91.68% 89.37% 89.63% 91.77%
Share Based Compensation of Revenue
16.57% 14.68% 13.26% 12.42%
Interest Coverage
(27.97) (25.43) (32.60) (37.09)
Operating CF/Net income
0.44 0.51 0.38 0.37
Depreciation/Fixed assets
17.71 18.45 17.80 12.11
Capex/Depreciation
(0.04) (0.05) (0.03) (0.07)
Revenue per Share
11.22 12.83 13.83 14.99
Operating CF per Share
(2.02) (1.88) (1.38) (1.38)
Capex per Share
(0.01) (0.01) (0.01) (0.01)
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates